Modern principles of diagnosis and treatment of severe traumatic brain injury

Authors

  • V.I. Cherniy State Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of the Agency of State Affairs, Kyiv, Ukraine
  • T.V. Cherniy State Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of the Agency of State Affairs, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0586.17.5.2021.240700

Keywords:

traumatic brain injury, comprehensive cytoprotective program, Neurocitin®, Lodixem®

Abstract

Traumatic brain injury (TBI) is a heterogeneous syndrome that includes various types of trauma. About 10–15 % of patients have severe TBI, accompanied by high rates of disability and mortality. Currently, the methods of intensive care from the standpoint of evidence-based medicine are widely used for their treatment. Along with intensive care, the comprehensive cytoprotective program using Neurocitin®, which contains citicoline and electrolytes, is of great importance. Neurocitin® has a combined effect aimed at correcting metabolic and volemic disorders, namely, maintaining adequate cerebral perfusion, timely elimination of water-electrolyte disorders, energy supply of brain tissues and protection of the neurovascular unit from damage. Lactate in the composition of Neurocitin® provides a detoxification effect, preserves and increases the energy supply of neurons, improves metabolism, cerebral blood flow and neuronal activity. For the treatment of TBI, the neurometabolic drug of ethylmethylhydroxypyridine succinate (Lodixem®) is also used. Lodixem® normalizes cerebral blood flow, provides an earlier resolution of post-traumatic encephalopathy and restoration of consciousness, leads to a decrease in the severity of endogenous intoxication syndrome, the elimination of pathological vicious circles that arise against the background of hypoxia, ischemia and energy deficiency in various organs and tissues.

Downloads

Download data is not yet available.

References

Huijben J. Assessment and Improvement of Intensive Care for patients with Traumatic Brain Injury. 2021.

Guidelines of severe traumatic brain injury. 3rd edition. Journal of Neurotrauma. 2007. Vol. 24. P 43-52.

Guidelines for the Management of Severe Traumatic Brain Injury. Fourth еdition. 2016.

A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC) Randall Chesnut1 et al. Intensive Care Med. 2020. Vol. 46(5). P. 919-929. https://doi.org/10.1007/s00134-019-05900-x.

Дадаев Х.Х., Сабиров Д.М., Юлдашев Ф.А., Красненкова М.Б. Аналгоседация в интенсивной терапии тяжелой черепно-мозговой травмы. Вестник экстренной медицины. 2015. № 2. С. 60-65.

Потиевская В.И., Гридчик И.Е., Грицан А.И., Еременко А.А., Заболотских И.Б., Козлов И.А., Лебединский К.М., Левит А.Л., Мазурок В.А., Молчанов И.В., Николаенко Э.М., Овечкин А.М. Седация пациентов в отделениях реанимации и интенсивной терапии. Российский журнал анестезиологии и реаниматологии. 2018. Vol. 63(2). С. 165-175. DOI: http://dx.doi.org/10.18821/0201-7563-2018-63-2-165-175.

Brown E.N., Pavone K.J., Naranjo М. Multimodal General Anesthesia: Theory and Practice. AnesthAnalg. 2018. Vol. 127. P. 1246-58. DOI: 10.1213/ANE.0000000000003668.

Constantin J.M., Momon A., Mantz J., Payen J.F., De Jonghe B., Perbet S. et al. Efficacy and safety of sedation with dexmedetomidine in critical care patients: A meta-analysis of randomized controlled trials. Anaesth. Crit. Care Pain Med. 2015. Vol. 35(1). P. 7-15. DOI: 10.1016/j.accpm.2015.06.012.

Zhang Z., Chen K., Ni H., Zhang X., Fan H. Sedation of mechanically ventilated adults in intensive care unit: a network meta-analysis. Sci. Rep. 2017. Vol. 7. P. 449-79. DOI: 10.1038/srep44979.

Арефьев А.М., Куликов А.С., Лубнин А.Ю. Дексмедетомидин в нейроанестезиологии. Анестезиология и реаниматология. 2017. Vol. 62(3). P. 213-219. DOI: http://dx.doi.org/10.18821/0201-7563-2017-62-3-213-219.

Сергеев Д.В., Домащенко M.A., Пирадов M.A. Фармакологическая нейропротекция при ишемическом инсульте в реальных клинических условиях. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017. Vol. 117(4). P. 86-91.

Agarwal S., Patel B.M. Is aura around citicoline fading? A systemic review. Indian J. Pharmacol. 2017. Vol. 49(1). P. 4-9. DOI: 10.4103/0253-7613.201037.

Secades J.J. Role of citicoline in the management of traumatic brain injury. Pharmaceuticals. 2021. Vol. 14. P. 410. DOI: 10.3390/ph14050410.

Никонов В.В., Чернов А.Л., Феськов А.Э., Соколов А.С., Белецкий А.В. Возможности применения этилметилгидроксипиридина сукцината в комплексной интенсивной терапии острого периода черепно-мозговой травмы. Міжнародний неврологічний журнал. 2018. № 7. C. 28-33. DOI: 10.22141/2224-0713.7.101.2018.149663.

Servadei F., Kolias A., Kirollos R., Khan T., Hutchinson P. Cisternostomy for traumatic brain injury-rigorous evaluation is ne-cessary. Acta Neurochirurgica. 2020. № 3. https://doi.org/10.1007/s00701-020-04224-w.

Published

2022-01-10

How to Cite

Cherniy, V., & Cherniy, T. (2022). Modern principles of diagnosis and treatment of severe traumatic brain injury. EMERGENCY MEDICINE, 17(5), 6–12. https://doi.org/10.22141/2224-0586.17.5.2021.240700

Issue

Section

Lecture

Most read articles by the same author(s)

1 2 3 > >>